Giovanni Barosi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6394841/publications.pdf

Version: 2024-02-01

171 papers	16,421 citations	27035 58 h-index	17891 125 g-index
173 all docs	173 docs citations	173 times ranked	9416 citing authors

#	Article	IF	Citations
1	Transplant indications, guidelines and recommendations: Caveat Emptor. Bone Marrow Transplantation, 2022, 57, 149-151.	1.3	2
2	Everyone is entitled to his or her own opinion but not to their own facts*. British Journal of Haematology, 2022, 196, 1290-1292.	1.2	0
3	Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel. Critical Reviews in Oncology/Hematology, 2022, 172, 103623.	2.0	7
4	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology,the, 2022, 9, e301-e311.	2.2	46
5	Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story. Blood Advances, 2022, 6, 2331-2333.	2.5	13
6	Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia, 2021, 35, 468-475.	3.3	7
7	Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. Leukemia, 2021, 35, 1197-1202.	3.3	9
8	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	2.5	8
9	COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021034.	0.5	4
10	Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis. Cancers, 2021, 13, 2552.	1.7	9
11	Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes. Genes, 2021, 12, 1271.	1.0	4
12	New Markers of Disease Progression in Myelofibrosis. Cancers, 2021, 13, 5324.	1.7	6
13	Primary myelofibrosis: rs2010963 VEGFA polymorphism favors a prefibrotic phenotype and is associated with higher risk of thrombosis. Leukemia Research, 2021, 111, 106730.	0.4	3
14	VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis. TH Open, 2021, 05, e513-e520.	0.7	1
15	Plasma sIL-2RÎ± levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation. Leukemia Research, 2020, 90, 106319.	0.4	7
16	Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. Blood, 2020, 135, 133-144.	0.6	52
17	Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. Blood Cancer Journal, 2019, 9, 61.	2.8	25
18	Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity. PLoS ONE, 2019, 14, e0220189.	1.1	3

#	Article	IF	Citations
19	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. Blood Reviews, 2019, 34, 84-94.	2.8	35
20	Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?. Leukemia, 2019, 33, 588-596.	3.3	8
21	Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. Blood, 2019, 133, 2802-2808.	0.6	12
22	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. Leukemia Research, 2019, 81, 88-94.	0.4	11
23	Response to the Commentary on â€œIs posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myelomaâ€• Leukemia, 2019, 33, 1301-1302.	3.3	0
24	Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Advances, 2019, 3, 1729-1737.	2.5	105
25	Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation, 2019, 25, 855-860.	2.0	13
26	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	3.3	415
27	Is there expert consensus on expert consensus?. Bone Marrow Transplantation, 2018, 53, 1055-1060.	1.3	15
28	The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. American Journal of Hematology, 2018, 93, 615-622.	2.0	8
29	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 310-318.	0.8	373
30	Role of TGF â€Î²1/miRâ€382â€5p/ SOD 2 axis in the induction of oxidative stress in CD 34+ cells from primary myelofibrosis. Molecular Oncology, 2018, 12, 2102-2123.	2.1	19
31	Response to â€œQuestions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisionsâ€•by Heidel et al.. Leukemia, 2018, 32, 2727-2728.	3.3	2
32	Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia, 2018, 32, 2077-2081.	3.3	30
33	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disordersâ€“A consensus project of the Italian Society of Hematology. Leukemia Research, 2017, 58, 63-72.	0.4	25
34	Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leukemia Research, 2017, 60, 18-23.	0.4	27
35	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 2017, 129, 3227-3236.	0.6	137
36	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood, 2017, 130, 1768-1771.	0.6	52

#	Article	IF	Citations
37	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. American Journal of Hematology, 2017, 92, 1062-1067.	2.0	33
38	Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. American Journal of Pathology, 2017, 187, 1879-1892.	1.9	17
39	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. American Journal of Hematology, 2017, 92, 187-195.	2.0	41
40	CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. Oncotarget, 2017, 8, 54082-54095.	0.8	25
41	miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. Oncotarget, 2017, 8, 21380-21397.	0.8	13
42	Thrombopoietin/TGF-Î²1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis. Stem Cells, 2016, 34, 1123-1133.	1.4	49
43	Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in nonâ€Hodgkin lymphoma: a <scp>SIE</scp>,<scp> SIES</scp>, and <scp>GITMO</scp> consensus paper. European Journal of Haematology, 2016, 97, 554-561.	1.1	9
44	Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis. Blood, 2016, 128, 1660-1662.	0.6	13
45	Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPNâ€associated myelofibrosis. American Journal of Hematology, 2016, 91, 709-713.	2.0	6
46	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Journal of Clinical Oncology, 2016, 34, 151-159.	0.8	56
47	Altered fibronectin expression and deposition by myeloproliferative neoplasmâ€derived mesenchymal stromal cells. British Journal of Haematology, 2016, 172, 140-144.	1.2	18
48	Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors. Biology of Blood and Marrow Transplantation, 2016, 22, 324-329.	2.0	56
49	Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis. PLoS ONE, 2016, 11, e0156990.	1.1	3
50	Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal. Clinical Investigation, 2015, 5, 643-651.	0.0	0
51	Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis. OncoTargets and Therapy, 2015, 8, 1091.	1.0	17
52	Dysregulation of VEGF-induced proangiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony-forming cells. Experimental Hematology, 2015, 43, 1019-1030.e3.	0.2	46
53	Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 507-513.	0.2	13
54	Activation of non-canonical TGF-Î²1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. Blood Cells, Molecules, and Diseases, 2015, 54, 234-241.	0.6	31

#	Article	IF	Citations
55	Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis. Current Hematologic Malignancy Reports, 2015, 10, 362-369.	1.2	1
56	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nature Communications, 2015, 6, 6691.	5.8	145
57	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 75-85.	0.2	32
58	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 2014, 124, 1062-1069.	0.6	340
59	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer, 2014, 120, 513-520.	2.0	165
60	Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter. Best Practice and Research in Clinical Haematology, 2014, 27, 129-140.	0.7	43
61	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leukemia Research, 2014, 38, 1269-1277.	0.4	13
62	An Immune Dysregulation in MPN. Current Hematologic Malignancy Reports, 2014, 9, 331-339.	1.2	75
63	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. Leukemia Research, 2014, 38, 155-160.	0.4	28
64	CD14brightCD16low intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis. Experimental Hematology, 2014, 42, 244-246.	0.2	9
65	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood, 2014, 124, e21-e32.	0.6	105
66	A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group. Blood, 2014, 124, 3192-3192.	0.6	1
67	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. Blood, 2014, 124, 405-405.	0.6	47
68	Enhanced Expression of Stim, Orai, and TRPC Transcripts and Proteins in Endothelial Progenitor Cells Isolated from Patients with Primary Myelofibrosis. PLoS ONE, 2014, 9, e91099.	1.1	60
69	A phase II study of <scp>G</scp>ivinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. British Journal of Haematology, 2013, 161, 688-694.	1.2	109
70	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood, 2013, 122, 1395-1398.	0.6	286
71	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood, 2013, 122, 4047-4053.	0.6	383
72	<scp>SIE</scp>, <scp>SIES</scp>, <scp>GITMO</scp> revised guidelines for the management of follicular lymphoma. American Journal of Hematology, 2013, 88, 185-192.	2.0	32

#	Article	IF	Citations
73	No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis. Haematologica, 2013, 98, e83-e84.	1.7	4
74	Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood, 2013, 121, 360-368.	0.6	102
75	Characterization of the TGF-Î²1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood, 2013, 121, 3345-3363.	0.6	86
76	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood, 2013, 121, 4778-4781.	0.6	219
77	Involvement of TGFÂ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis. Haematologica, 2013, 98, 514-517.	1.7	29
78	The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT). Blood, 2013, 122, 4070-4070.	0.6	15
79	JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis. PLoS ONE, 2013, 8, e59791.	1.1	15
80	Emerging targeted therapies in myelofibrosis. Expert Review of Hematology, 2012, 5, 313-324.	1.0	4
81	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. Journal of Clinical Oncology, 2012, 30, 4098-4103.	0.8	344
82	JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine, 2012, 366, 787-798.	13.9	1,543
83	A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood, 2012, 120, 3112-3117.	0.6	33
84	Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis. PLoS ONE, 2012, 7, e35631.	1.1	85
85	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Annals of Hematology, 2012, 91, 875-888.	0.8	28
86	JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. Leukemia Research, 2012, 36, e7-e9.	0.4	17
87	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. Leukemia Research, 2012, 36, 459-466.	0.4	7
88	Management of Myeloproliferative Neoplasms: From Academic Guidelines to Clinical Practice. Current Hematologic Malignancy Reports, 2012, 7, 50-56.	1.2	19
89	Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera. Blood, 2012, 120, 804-804.	0.6	6
90	Current Clinical Needs. , 2012, , 149-161.		0

#	Article	IF	Citations
91	Evaluation of the bioactive and total transforming growth factor Î²1 levels in primary myelofibrosis. Cytokine, 2011, 53, 100-106.	1.4	29
92	In Vitro Megakaryocyte Differentiation and Proplatelet Formation in Ph-Negative Classical Myeloproliferative Neoplasms: Distinct Patterns in the Different Clinical Phenotypes. PLoS ONE, 2011, 6, e21015.	1.1	48
93	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood, 2011, 118, 401-408.	0.6	280
94	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood, 2011, 118, 2069-2076.	0.6	144
95	EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 2011, 118, 5227-5234.	0.6	242
96	The European LeukemiaNet: achievements and perspectives. Haematologica, 2011, 96, 156-162.	1.7	15
97	Splenectomy produces a rapid but transient decrease of the frequency of circulating CD34⁺ haematopoietic progenitor cells in primary myelofibrosis. British Journal of Haematology, 2011, 152, 665-667.	1.2	3
98	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	0.8	724
99	Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: Deconstructing a myth?. Leukemia Research, 2011, 35, 563-565.	0.4	4
100	Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy, 2011, 12, 1597-1611.	0.9	25
101	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica, 2011, 96, 315-318.	1.7	160
102	Conventional and Investigational Therapy for Primary Myelofibrosis. , 2011, , 117-138.		1
103	Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood, 2010, 116, 1051-1055.	0.6	56
104	Consensus conference on the use of 90â€yttriumâ€ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology. American Journal of Hematology, 2010, 85, 147-155.	2.0	5
105	Phase I/II study of singleâ€agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. American Journal of Hematology, 2010, 85, 616-619.	2.0	18
106	Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?. Leukemia Research, 2010, 34, 1119-1120.	0.4	16
107	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 2010, 148, 961-963.	1.2	144
108	A pilot study of the Histoneâ€Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology, 2010, 150, 446-455.	1.2	202

#	Article	IF	Citations
109	High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis. PLoS ONE, 2010, 5, e15277.	1.1	30
110	Thrombosis in primary myelofibrosis: incidence and risk factors. Blood, 2010, 115, 778-782.	0.6	216
111	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 2009, 113, 4829-4833.	0.6	229
112	Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. Journal of Clinical Oncology, 2009, 27, 4563-4569.	0.8	213
113	Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2009, 94, 102-112.	1.7	23
114	JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica, 2009, 94, 144-146.	1.7	35
115	Novel strategies for patients with chronic myeloproliferative disorders. Current Opinion in Hematology, 2009, 16, 129-134.	1.2	11
116	Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica, 2009, 94, 550-565.	1.7	66
117	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 2009, 113, 2895-2901.	0.6	1,110
118	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 2009, 114, 1477-1483.	0.6	196
119	Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. Blood, 2009, 114, 3127-3130.	0.6	79
120	Hypermethylation ofCXCR4Promoter in CD34+ Cells from Patients with Primary Myelofibrosis. Stem Cells, 2008, 26, 1920-1930.	1.4	91
121	A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2008, 10, 435-441.	1.2	47
122	From Palliation to Epigenetic Therapy in Myelofibrosis. Hematology American Society of Hematology Education Program, 2008, 2008, 83-91.	0.9	13
123	MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. Blood, 2008, 111, 4418-4418.	0.6	30
124	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood, 2008, 112, 844-847.	0.6	216
125	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 2007, 110, 1092-1097.	0.6	808
126	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood, 2007, 110, 4030-4036.	0.6	233

#	Article	IF	Citations
127	New and Old Treatment Modalities in Primary Myelofibrosis. Cancer Journal (Sudbury, Mass), 2007, 13, 377-383.	1.0	53
128	The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells, Molecules, and Diseases, 2007, 38, 280-286.	0.6	60
129	Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood, 2007, 110, 986-993.	0.6	186
130	Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica, 2007, 92, 95-100.	1.7	341
131	Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leukemia Research, 2007, 31, 737-740.	0.4	288
132	Anaemia characterises patients with myelofibrosis harbouring MplW515L/Kmutation. British Journal of Haematology, 2007, 137, 244-247.	1.2	153
133	New consensus: a unified definition of clinical resistance and/or intolerance to hydroxyurea in essential thrombocythaemia. European Journal of Haematology, 2007, 79, 24-26.	1.1	2
134	Molecular Profiling of CD34+Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1). Stem Cells, 2007, 25, 165-173.	1.4	111
135	Management of Myelofibrosis. , 2007, , 125-142.		1
136	Myelofibrosis with myeloid metaplasia: Disease overview and non-transplant treatment options. Best Practice and Research in Clinical Haematology, 2006, 19, 495-517.	0.7	31
137	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 2006, 108, 1497-1503.	0.6	317
138	Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Current Opinion in Hematology, 2006, 13, 74-78.	1.2	10
139	Role of theJAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology, 2006, 44, 1528-1534.	3.6	249
140	Quantitative Evaluation of Bone Marrow Angiogenesis in Idiopathic Myelofibrosis. American Journal of Clinical Pathology, 2006, 126, 241-247.	0.4	34
141	Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. American Journal of Clinical Pathology, 2006, 126, 241-7.	0.4	13
142	Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2006, 91, 96-103.	1.7	30
143	Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2006, 91, 1662-73.	1.7	32
144	Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood, 2005, 105, 4508-4515.	0.6	106

#	Article	IF	Citations
145	Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood, 2005, 105, 4115-4119.	0.6	194
146	Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood, 2005, 106, 2849-2853.	0.6	75
147	The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood, 2005, 105, 1699-1705.	0.6	58
148	Myelofibrosis With Myeloid Metaplasia: Diagnosis, Prognostic Factors, and Staging. Seminars in Oncology, 2005, 32, 395-402.	0.8	23
149	Studies of the Site and Distribution of CD34+ Cells in Idiopathic Myelofibrosis. American Journal of Clinical Pathology, 2005, 123, 833-839.	0.4	17
150	Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2â€“Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia. Journal of Clinical Oncology, 2005, 23, 5688-5695.	0.8	81
151	Idiopathic Myelofibrosis. Seminars in Hematology, 2005, 42, 248-258.	1.8	35
152	Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica, 2005, 90, 1236-57.	1.7	30
153	Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial. Journal of Clinical Oncology, 2004, 22, 424-431.	0.8	134
154	Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 2004, 124, 618-625.	1.2	43
155	Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2004, 89, 215-32.	1.7	199
156	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica, 2004, 89, 717-41.	1.7	48
157	Chronic Myeloproliferative Disorders. Hematology American Society of Hematology Education Program, 2003, 2003, 200-224.	0.9	101
158	Myelofibrosis with myeloid metaplasia. Hematology/Oncology Clinics of North America, 2003, 17, 1211-1226.	0.9	35
159	Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies. Leukemia and Lymphoma, 2002, 43, 2301-2307.	0.6	90
160	High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy. Haematologica, 2002, 87, 472-8.	1.7	5
161	Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Blood, 2001, 98, 3249-3255.	0.6	197
162	Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 2001, 114, 78-83.	1.2	85

#	Article	IF	Citations
163	Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. European Journal of Haematology, 2001, 66, 324-327.	1.1	26
164	Deciding when to intervene: a Markov decision process approach. International Journal of Medical Informatics, 2000, 60, 237-253.	1.6	40
165	Myelofibrosis With Myeloid Metaplasia: Diagnostic Definition and Prognostic Classification for Clinical Studies and Treatment Guidelines. Journal of Clinical Oncology, 1999, 17, 2954-2954.	0.8	208
166	The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. British Journal of Haematology, 1999, 104, 730-737.	1.2	179
167	Myelofibrosis with myeloid metaplasia in young indidviduals: disease characteristics, prognostic factors and identification of risk groups. British Journal of Haematology, 1998, 102, 684-690.	1.2	168
168	Erythropoietin production and erythropoiesis in compensated and anaemic states of hereditary spherocytosis. British Journal of Haematology, 1996, 92, 150-154.	1.2	25
169	An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer, 1991, 68, 2310-2318.	2.0	33
170	A prognostic classification of myelofibrosis with myeloid metaplasia. British Journal of Haematology, 1988, 70, 397-401.	1.2	115
171	Red cell aplasia in myelofibrosis with myeloid metaplasia. A distinct functional and clinical entity. Cancer, 1983, 52, 1290-1296.	2.0	11